Behbahani Ali 4

What Happened

• Behbahani Ali, a director of Monte Rosa Therapeutics, reported related-party distributions on July 1, 2026. The filing shows: a pro rata distribution by NEA 17 of 1,000,000 shares (reported as a disposition, $0.00 per share), an acquisition of 15,000 shares by NEA Partners 17 (reported at $0.00), and a subsequent distribution by NEA Partners 17 of 15,000 shares (reported as a disposition, $0.00). These transactions were internal distributions among NEA-affiliated entities and involved no cash proceeds.

Key Details

• Transaction date(s): July 1, 2026
• Reported prices: $0.00 per share for all transactions (pro rata distributions / no consideration)
• Notable footnotes:
  • NEA 17 made a pro rata distribution of 1,000,000 shares to its GP and LPs (F1).
  • The reporting person is manager of NEA 17 GP and disclaims beneficial ownership of securities in which they have no pecuniary interest (F2, F4).
  • NEA Partners 17 received 15,000 shares in the NEA 17 distribution (F3) and then distributed 15,000 shares for no consideration (F5).
• Shares owned after the transaction: not specified in the filing.
• Filing timeliness: Form filed July 6, 2026 for a July 1 transaction. Section 16 filings are generally required within two business days; this filing appears to have been submitted after that window.

Context

• These were internal entity distributions (code J) among venture capital/partnership entities affiliated with the reporting person, not open-market sales or purchases by the director personally. Because the reporting person disclaims beneficial ownership of portions where they have no pecuniary interest, these entries reflect institutional reallocation rather than a personal buy/sell decision. Such distributions typically do not signal the director’s personal market view.